Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Zogenix, Inc. Corporation Investors

    0
    246
    Reading Time: 2 minutes

    LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24ZGNX&src=ctag” target=”_blank”gt;$ZGNXlt;/agt; lt;a href=”https://twitter.com/hashtag/CLASSACTION?src=hash” target=”_blank”gt;#CLASSACTIONlt;/agt;–Glancy
    Prongay & Murray LLP
    (“GPM”), a national investors rights law
    firm, announces that a class action lawsuit has been filed on behalf of
    investors that acquired Zogenix, Inc. (“Zogenix” or the “Company”)
    (NASDAQ: ZGNX)
    securities between February 6, 2019 and April 8, 2019, inclusive
    (the “Class Period”). Zogenix investors have until June 11, 2019 to
    file a lead plaintiff motion.

    If you are a shareholder who suffered a loss, click here
    to participate.

    If you wish to learn more about this action, or if you have any
    questions concerning this announcement or your rights or interests with
    respect to these matters, please contact Lesley Portnoy, Esquire, at
    310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected],
    or visit our website at www.glancylaw.com.

    On April 8, 2019, Zogenix announced that it received a refusal to file
    letter from the U.S. Food and Drug Administration (“FDA”) regarding
    Zogenix’s new drug application (“NDA”) for FINTEPLA, Zogenix’s proposed
    treatment for seizures associated with Dravet syndrome. The FDA
    determined that the NDA was not sufficiently complete to permit a
    substantive review because certain non-clinical studies were not
    submitted to allow assessment of the chronic administration of
    fenfluramine, and the application contained an incorrect version of a
    clinical dataset. On this news, shares of Zogenix fell $11.89 or nearly
    23% to close at $39.96 per share on April 9, 2019, thereby injuring
    investors.

    The complaint filed in this class action alleges that throughout the
    Class Period, Defendants made materially false and/or misleading
    statements, as well as failed to disclose material adverse facts about
    the Company’s business, operations, and prospects. Specifically,
    Defendants failed to disclose to investors: (1) Zogenix’s NDA for
    FINTEPLA contained inadequate non-clinical data and an incorrect version
    of a clinical dataset; (2) consequently, Zogenix’s NDA for FINTEPLA was
    unlikely to gain FDA approval; and (3) as a result, the Company’s public
    statements were materially false and misleading at all relevant times.

    Follow us for updates on Twitter: twitter.com/GPM_LLP.

    If you purchased shares of Zogenix during the Class Period you may move
    the Court no later than June 11, 2019 to ask the Court
    to appoint you as lead plaintiff. To be a member of the Class you need
    not take any action at this time; you may retain counsel of your choice
    or take no action and remain an absent member of the Class. If you wish
    to learn more about this action, or if you have any questions concerning
    this announcement or your rights or interests with respect to these
    matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century
    Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150,
    Toll-Free at 888-773-9224, by email to [email protected],
    or visit our website at www.glancylaw.com.
    If you inquire by email please include your mailing address, telephone
    number and number of shares purchased.

    This press release may be considered Attorney Advertising in some
    jurisdictions under the applicable law and ethical rules.

    Contacts

    Glancy Prongay & Murray LLP, Los Angeles
    Lesley Portnoy,
    310-201-9150 or 888-773-9224
    www.glancylaw.com
    [email protected]